Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2016

Collaboration Agreement [Abstract]

Collaboration revenue with related party

The collaboration revenue the Company earned from Sanofi is detailed below:

	Three Months Ended June 30,
Sanofi Collaboration Revenue	2016			2015
Antibody:
Reimbursement of Regeneron research and development expenses	$	144,232		$	211,516
Reimbursement of Regeneron commercialization-related expenses	85,885			27,347
Regeneron's share of losses in connection with commercialization of antibodies	(122,107		)	(46,313		)
Other	3,054			2,560
Total Antibody	111,064			195,110
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	32,350			—
Other	20,000			—
Total Immuno-oncology	52,350			—
	$	163,414		$	195,110

	Six Months Ended June 30,
Sanofi Collaboration Revenue	2016			2015
Antibody:
Reimbursement of Regeneron research and development expenses	$	337,834		$	380,336
Reimbursement of Regeneron commercialization-related expenses	159,159			35,805
Regeneron's share of losses in connection with commercialization of antibodies	(221,529		)	(68,718		)
Other	6,019			5,121
Total Antibody	281,483			352,544
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	61,625			—
Other	40,000			—
Total Immuno-oncology	101,625			—
ZALTRAP:
Reimbursement of Regeneron research and development expenses	—			686
Other	—			15,236
Total ZALTRAP	—			15,922
	$	383,108		$	368,466

Collaboration revenue

The collaboration revenue the Company earned from Bayer is detailed below:

	Three Months Ended June 30,
Bayer Collaboration Revenue	2016		2015
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	167,492	$	106,631
Cost-sharing of Regeneron EYLEA development expenses	2,224		2,464
Other	13,355		16,618
Total EYLEA	183,071		125,713
PDGFR-beta antibody:
Cost-sharing of rinucumab/aflibercept (REGN2176-3) development expenses	2,762		5,926
Other	2,607		2,598
Total PDGFR-beta	5,369		8,524
Ang2 antibody:
Cost-sharing of nesvacumab/aflibercept (REGN910-3) development expenses	2,074		—
Other	1,382		—
Total Ang2	3,456		—
	$	191,896	$	134,237

	Six Months Ended June 30,
Bayer Collaboration Revenue	2016		2015
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	313,327	$	196,057
Sales milestones	—		15,000
Cost-sharing of Regeneron EYLEA development expenses	4,967		5,121
Other	39,847		29,530
Total EYLEA	358,141		245,708
PDGFR-beta antibody:
Cost-sharing of rinucumab/aflibercept (REGN2176-3) development expenses	4,658		7,180
Other	5,233		5,195
Total PDGFR-beta antibody	9,891		12,375
Ang2 antibody:
Cost-sharing of nesvacumab/aflibercept (REGN910-3) development expenses	2,074		—
Other	1,382		—
Total Ang2 antibody	3,456		—
	$	371,488	$	258,083